Ovid TherapeuticsOVID
Recorded

Ovid Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Aidan BrackenDirector Investment Banking

Good afternoon, everyone. My name is Aidan Bracken. I am a Director on the U.S.-based UBS Biotechnology Investment Banking Team. Thank you for everyone who has presented today and attending our inaugural 2026 Biopharma Conference here at the Rosewood. It is my pleasure to introduce Ovid Therapeutics and the President and CEO, Meg Alexander.

Meg AlexanderPresident and CEO

Thank you very much, Aidan. Good afternoon, everyone. It is my pleasure to give you an update today on our company, Ovid Therapeutics. At Ovid, we are dedicated to pioneering better and gentler medicines for brain diseases. Ovid is a publicly traded company, and we will be making forward-looking statements today. I am excited to tell you about Ovid, not just about the company we are, but because this is a really important time for the company. I would say at this point, we are in the playoffs and maybe headed to the Super Bowl. Perhaps not the right analogy for the Brits, but we are an American company. Our strategy at Ovid is really what you see in front of you.

Meg AlexanderPresident and CEO

Several years ago, we looked out at the field of neurology and neuropsychiatry, and it was a little depressing, because when you looked at pipelines from the pre-clinic straight through to marketed medicines, we could see that essentially drug development for the CNS was what I would call a sea of sameness, where many of our peers in the space were going after targets that were already known with mechanisms of action that had slightly better pharmacology or chemistry. That is important. We all want better medicines, but they were not going to be a step change for patients. We embarked upon a very deliberate strategy to build and curate our pipeline at Ovid. That is really what you see in front of you.

Meg AlexanderPresident and CEO

We wanted to go after fundamental targets that help regulate the balance of excitation and inhibition of neurons in the brain, and that we thought would have potentially broad potential in so doing. We wanted to go with differentiated mechanisms of action, because again, with a sea of sameness, we wanted to really try to bring a step change for patients, and we thought this might also translate into bigger commercial opportunities if we are able to differentiate our assets. Then finally, we were going after small molecule targets, because at the end of the day, we want medicines that are easy for patients to take. It took some time, but now we have a fully integrated pipeline, and we have actually four major readouts coming in the next six and 12 months, and it is very exciting.

Meg AlexanderPresident and CEO

It is happening across this pipeline that you see in front of you. As I said, it is a busy time, and we have a very replete pipeline. I will start at the top of the pipeline, and then we will go down to the bottom. Essentially, we have very exciting mechanisms of action that work different ways on GABA, the main braking, basically, system in the brain, or the main inhibitory neurotransmitter in the brain. I will start with these basically programs that are sort of a greenish teal. These are multiple proof of signal and proof of concept studies that are running for what is our program called OV329, which is a program, essentially the mechanism inhibits the main enzyme that eats GABA or catabolizes GABA, again, the main inhibitory neurotransmitter in the brain.

Meg AlexanderPresident and CEO

We are embarking on multiple epilepsy studies, including a phase II study that is running right now, and a photosensitivity study, which is a very interesting translational study that is going to read out in just a couple months from now, that should significantly de-risk the doses that we are taking into our pivotal studies. Why this is an exciting program is this mechanism has been validated before, but it was essentially validated by a very crude first-generation drug that had a lot of tolerability, safety baggage that we have subsequently unpacked. We now know that we have a safe version of this mechanism, so we are taking it into focal epilepsy in adults, but it has broad potential therapeutic utility.

Meg AlexanderPresident and CEO

We have also created a pediatric formulation of this program, OV329, and we are really excited to now unlock its potentials in some very severe forms of pediatric epilepsy, where we know this mechanism should work, and that is seizures associated with tuberous sclerosis complex, as well as infantile spasms. I will talk a little bit more about that. Those programs are underway, and moving into the clinic in the pediatric instance. Below that, these purple programs, is a very exciting portfolio of molecules that activate a target called KCC2. KCC2 stands for potassium chloride co-transporter two, and KCC2 is the target in the brain that clinicians, large pharmaceutical companies have wanted to drug for two decades, but it is extremely hard to drug. Now we have done it, and we have an oral KCC2 direct activator that is in the clinic and progressing well, and that is OV4071.

Meg AlexanderPresident and CEO

We have learned a lot about how to drug this target in the span of the last three to four years, where we have had to work through new questions and new challenges, and as a result, we have a discovery engine that sits underneath of it. KCC2 is a much wanted target to drug because the therapeutic applicability of drugging this target is considered to be quite vast. No one has been able to prove it until recently, and now all of the pharmacodynamic work that we have done in animals is suggesting that drugging KCC2 may really be true. We will talk about the domains that includes, but everything from forms of psychosis to seizures, pain, anxiety. These are some of the therapeutic area domains that KCC2 has been linked to, and we now have a molecule and data that is suggesting that it is indeed this broad.

Meg AlexanderPresident and CEO

It's a very exciting moment. We'll start with OV329, which is our epilepsy asset. Epilepsy has been a busier field of late, and that's a good thing for patients. We've got better medicines starting to come to the fore. Amazingly, despite knowing about seizures and epilepsy truly for millennia, seizure drugs haven't gotten that much better. What I mean by that is today, there's still so much unmet need despite really good work by some of my peers and friends in the space. What we don't have today is a drug that works really well to crush the seizures, that is safe and well-tolerated, doesn't make you feel poorly, and it's easy to use and works well in polypharmacy regimens. That sounds like a super vanilla profile, but in fact, nobody has been able to do that well yet.

Meg AlexanderPresident and CEO

OV329 may actually be stacking up to be the holy grail in epilepsy. With OV329, again, our epilepsy program, we know this is a validated mechanism for reducing seizures and a broad array of seizures. If we're at the right dose, it should work. It, by the way, works in more animal models for seizure than any seizure drug we've ever seen in development. It is rationally designed to be very potent, but also to have improved tolerability. We're seeing at doses where we know we deliver inhibition or restoring the braking system in the brain, it has better tolerability than any seizure medicine at this stage of development that has been trialed or that's even marketed. It's quite encouraging despite being early. It should be very easy to use. It doesn't interact with other drugs. It's once daily. It doesn't require titration.

Meg AlexanderPresident and CEO

It essentially would be a new mechanism of action for epilepsy because the first drug that tried to use this just had a lot of baggage, didn't work. This is very exciting, and we think its potential is broad to take across a number of epilepsies. Why we have conviction is we're trying to essentially replace what was a very crude first-generation medicine that was marketed by a company called Lundbeck that worked to reduce seizures, but it brought a lot of baggage along with it. If you see the slide behind me, you can see some of the epilepsies that this mechanism of action has previously been characterized in. The seizure reduction is quite profound if you look across the different epilepsies, both adult and pediatric. The safety was a real barrier to this.

Meg AlexanderPresident and CEO

The first-generation drug that we are subsequently replacing essentially preferentially partitioned in the eye and led to a form of irreversible blindness. Clearly, that's not acceptable, right? Reducing seizures is urgent. It's an emergency of the brain. Making somebody blind simultaneously, not an okay trade-off. Beyond that, it had a lot of tolerability issues, sedation among other things. Whereas with OV329, it was rationally designed by the same medicinal chemist who invented LYRICA, who then subsequently made it his life's work to do a better version of this mechanism. That's what OV329 is. Because of the therapeutic index that we've been able to carve with this medicine, we know that OV329 at our planned clinical doses can increase more GABA, again, the main inhibitory neurotransmitter, both in the synapse and in the extrasynaptic region, creating a more inhibitory environment around the neuron, so calming the excitation down.

Meg AlexanderPresident and CEO

Whereas the first-generation drug was so intolerable, it could not do that. It could only kind of blast levels of the main inhibitory neurotransmitter in the synapse, which also can lead to sedation and some tolerability issues that I could get into the technical reasons as to why. We believe with this more comprehensive form of inhibition that our drug is delivering, we may be able to be both more tolerable, but potentially drive more anticonvulsant efficacy as well. This is very encouraging to us, and we are asking and answering the right questions in the clinical trials to know this now. If we are right, the opportunity with OV329 could be significant.

Meg AlexanderPresident and CEO

What you see in front of you is both the potential market and the opportunity in adult focal onset seizures, as well as in pediatric epilepsies, including several of the developmental and epileptic encephalopathies that this is a validated mechanism for. What is very convenient for us is for OV329, not only can we develop different formulations, which helps from a pricing perspective, but it is also very needed for these populations. In infantile spasms and tuberous sclerosis complex seizures, we are dealing with babies and children. They cannot take a fixed-dose pill. They need a different type of formulation. We are pursuing basically a granule in a form of sachet, so it can mix into food or formula and things of that nature, whereas adults in the focal epilepsy need a pill.

Meg AlexanderPresident and CEO

This allows us to separate the two programs despite it being a similar mechanism of action, and to appropriately introduce them to the market, including pricing them separately. Significant opportunities, multi-billion dollar opportunities there. A really important step that we had to leap over in order for us, but importantly, the external world to have conviction in OV329 is, of course, that we were not going to have the same ophthalmic safety issues that the first-generation drug had. This meant a number of the killer experiments needing to be run, dedicated toxicology work for the eye. Essentially, what we have been able to show and what this slide shows is we proved what independent research had shown, which is that this first-generation drug, the compound, specifically to that compound, partitions and accumulates in the eye. We have proved it. At the same exposures for our drug, OV329, we get into the tissue very quickly, but then we clear it, and it is undetectable.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day